Medicxi Ventures Management’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-19,963,157
| Closed | -$793M | – | 4 |
|
|
2026
Q1 | $793M | Hold |
19,963,157
| – | – | 80.76% | 1 |
|
|
2025
Q4 | $499M | Hold |
19,963,157
| – | – | 59.8% | 1 |
|
|
2025
Q3 | $484M | Hold |
19,963,157
| – | – | 65.03% | 1 |
|
|
2025
Q2 | $262M | Hold |
19,963,157
| – | – | 61.4% | 1 |
|
|
2025
Q1 | $287M | Hold |
19,963,157
| – | – | 65.59% | 1 |
|
|
2024
Q4 | $334M | Hold |
19,963,157
| – | – | 63.2% | 1 |
|
|
2024
Q3 | $319M | Hold |
19,963,157
| – | – | 60.35% | 1 |
|
|
2024
Q2 | $180M | Hold |
19,963,157
| – | – | 53.77% | 1 |
|
|
2024
Q1 | $226M | Hold |
19,963,157
| – | – | 50.22% | 1 |
|
|
2023
Q4 | $159M | Hold |
19,963,157
| – | – | 53.64% | 1 |
|
|
2023
Q3 | $129M | Hold |
19,963,157
| – | – | 41.24% | 1 |
|
|
2023
Q2 | $124M | Hold |
19,963,157
| – | – | 34.62% | 1 |
|
|
2023
Q1 | $76.9M | Hold |
19,963,157
| – | – | 32.93% | 1 |
|
|
2022
Q4 | $61.9M | Hold |
19,963,157
| – | – | 25.99% | 2 |
|
|
2022
Q3 | $80.3M | Hold |
19,963,157
| – | – | 33.41% | 1 |
|
|
2022
Q2 | $97.2M | Hold |
19,963,157
| – | – | 40.37% | 1 |
|
|
2022
Q1 | $179M | Buy |
19,963,157
+1,839,265
| +10% | +$16.8M | 48.51% | 1 |
|
|
2021
Q4 | $204M | Buy |
18,123,892
+200,000
| +1% | +$2.69M | 51.07% | 1 |
|
|
2021
Q3 | $299M | Hold |
17,923,892
| – | – | 65.12% | 1 |
|
|
2021
Q2 | $398M | Buy |
+17,923,892
| New | +$421M | 71.34% | 1 |
|
Medicxi Ventures Management's CNTA Position: Q2 2026 in Review
Medicxi Ventures Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 19,963,157 shares — an estimated $793M sold.
Medicxi Ventures Management first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $793M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Medicxi Ventures Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Medicxi Ventures Management sold 19,963,157 Centessa Pharmaceuticals shares in Q2 2026, an estimated $793M.
- Medicxi Ventures Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Medicxi Ventures Management's Centessa Pharmaceuticals position peaked at $793M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Medicxi Ventures Management's 13F filing for Q2 2026, filed 4 Aug 2026.